Malaria Clinical Trial
Official title:
Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-Piperaquine for the Post-discharge Management of Severe Anaemia in Children Less Than 5 Years in Malawi
Background and rationale: Children hospitalised with severe anaemia in Africa are at high risk of readmission or death within 6 months after discharge. No strategy specifically addresses this post-discharge period. In Malawi, 3 months of post-discharge malaria chemoprevention (PMC) with monthly 3-day treatment courses of artemether-lumefantrine (AL) in children with severe malarial anaemia prevented 31% of deaths and readmissions. The effect was in addition to the effect of insecticide-treated bednets. There is now need to design and evaluate effective delivery mechanism for PMC within the health system.
Objectives: The primary objective of the trial is to determine the optimum PMC delivery
mechanism by comparing community- versus health facility-based strategies in order to inform
policy.
Study Type: This is a single-centre, matched, cluster randomized, 5-arm, factorial design
trial comparing the uptake of PMC-DHP delivered through health facility or community-based
approaches with or without SMS/HSA reminders.
Site: 90 villages in the catchment areas of Zomba Central hospital in southern Malawi
Study Population:
Inclusion criteria: convalescent children aged less than 5 years and weighing >5 kg admitted
with severe anaemia (haemoglobin<5g/dL / Ht<15%); clinically stable, able to take or switch
to oral medication; post-transfusion Hb >5g/dL.
Exclusion criteria: blood loss due to trauma, malignancy, known bleeding disorders or sickle
cell trait, known hypersensitivity to study drug, known heart conditions, non-resident in
study area, previous participation in study, known need at enrolment for prohibited
medication and scheduled surgery during the course of the study. HIV infection and
cotrimoxazole prophylaxis are not exclusion criteria
Study Interventions:
All children will receive Dihydroartemisinin-piperaquine (3-day treatment courses, given 2,6
and 10 weeks after discharge) either:
1. at discharge + SMS Reminder;
2. at discharge + No SMS Reminder;
3. at discharge + HSA Reminder;
4. at OPD + SMS Reminder; or
5. at OPD + No SMS Reminder
Outcome Measures:
Primary: 100% of PMC drugs uptake (defined as administration of all 3-day treatment courses,
given 2, 6 and 10 weeks after discharge) assessed by unannounced spot checks.
Follow-up procedures: Children will be followed up for 15 weeks by passive case detection in
2 phases: Pre-PMC (2 weeks between hospital admission and 2 weeks post-discharge); PMC (2-14
weeks post-discharge)
Sample Size: A sample size of 75 children per arm (375 total children) allows for a detection
of 25% increase in uptake from 50% to 75% with 10% loss to follow-up (power 90%, α=0.05).
Data Analysis: The % of children receiving IPTpd according to schedule will be compared by
relative risks (95% CI), adjusted for prognostic factors at baseline using log binomial or
Poisson regression with adjustment for cluster effects
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |